Personal Information
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
www.scitechdevelopment.com/
À propos
Clinical stage, biopharm company that has developed unique nano-delivery systems (SciTech Drug Delivery Vehicle - SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials* to be a safe and effective anticancer therapy with targeted cancer destroying activity. The combination of the new SDV and fenretinide has led to SCI’s first drug product, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives. SciTech's lead drug ST-001 is an IND approved immuno-oncology (IO), orphan drug, small molecule with an FDA roadmap to NDA post Phase 1b for multiple cancer indications
Mots-clés
fenretinide
nanofenretinide
st-001
scitech development
drug
drug delivery
scitech
cancer
nanoparticle
sdv
oncology
4-hpr
retinoid
phospholipids
mechanism of action
timothy kuzel
t-cell lymphoma
sars-cov-2
antivirus
antiviral
covid-19
investigational new drug
small cell lung cancer
pharmaceutical
brian leyland-jones
scitech drug delivery vehicle
io
immuno-oncology
opportunity
clinic ready
poster
4-hydroxy(phenyl)retinamide
immunotherapeutic
product pipeline
active pharmaceutical ingredient
louis m. scarmoutzos
michael burns
earle t. holsapple iii
anticancer
coronavirus
hpr
inflammation
ards
cytokine storm
viremia
therapeutic
sars
pediatric
paediatric
neuroblastoma
leukemia
ewing’s sarcoma family of tumours
esft
aml
all
acute myelogenous leukemia
acute lymphocytic leukemia
sclc
orphan drug
fda roadmap
executive summary
scientific formulation
ralph e. parchment
pharmaceutical development
michael w. young
elizabeth kraus
clinical strategy
christine d. copple
andrew stumpf
targeted cancer indications
scitech delivery vehicle
proprietary technology
competiton
bioavailability
addressable market sizes
r/r
relapsed/refractory
clinical trial
phase 1a/1b
fenretinide phospholipid suspension
t-cell non-hodgkin's lymphoma
ash 2019
steve munk
senior
scientists
product development
physicians
oncologist
kenneth massey
john doux
investor
gregory kalemkerian
executives
clinicians
board of advisors
biotech
advisory board
chinese
china
abstract
title
china biomed innovation and investment conference
cbic
employment
infrastructure savings
cost of care
economic development
quality of life
therapeutic reach
drug costs
cancer healthcare
social impact
economic impact
social and economic impact
socioeconomic
faq
fda approval
innate
agents
immunotherapy
treatment
ancillary
cancer remission
cancer indications
earle holsapple
funding
investment
data driven
snapshot
redefining early stage investments
resi
synthetic
lamellae
multilayers
bilayers
self assembly
molecular architecture
triglyceride free
self assemble
retinoid receptors
rar/rare
oxygen radicals
nanovesicle
nanofenrtinide
mitrochondrial oxphos
des-1
deficient adaptive immunity
ceramide inhibition
apoptosis
api
ayad al-katib
bioavailable
suspension
phospholipid
agent
ctcl
non-hodgkin lymphoma
testimonials
Tout plus
- Présentations
- Documents
- Infographies